Genetic Technologies Limited (NASDAQ:GENE)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.12 and traded as high as $1.85. Genetic Technologies shares last traded at $1.85, with a volume of 200 shares trading hands.
Separately, ValuEngine raised shares of Genetic Technologies from a “hold” rating to a “buy” rating in a research note on Wednesday, September 4th.
The firm’s 50 day moving average price is $1.97 and its two-hundred day moving average price is $1.12.
About Genetic Technologies (NASDAQ:GENE)
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Featured Story: Trading Ex-Dividend Strategy
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.